Human Microbiome Market Growth (22.2% CAGR) Led by Probiotics Segment Held Market Share of 24.71% in 2021: The Insight Partners

The Insight Partners published latest research report on "Human Microbiome Market Size Report, Scope, Trends, Revenue, Share Forecast to 2028 - COVID-19 Impact and Global Analysis By Product, Disease, Application and Geography," the global market size is expected to reach USD 2,921.68 million by 2028 from USD 718.95 million in 2021; it is estimated to grow at a CAGR of 22.2% during 2021–2028.

Download PDF Brochure:

Global Human Microbiome Market Growth Drivers:

•           Increasing Awareness: As more people become aware of the importance of gut health and the role of the human microbiome in overall health, the demand for human microbiome-related products and services is expected to increase.

•           Advancements in Research: Advances in human microbiome research have led to a better understanding of the role of the human microbiome in health and disease. This has led to the development of new products and services that target specific conditions and diseases.

•           Increasing Prevalence of Chronic Diseases: Chronic diseases such as diabetes, obesity, and inflammatory bowel disease are becoming more prevalent, and there is increasing evidence that the microbiome plays a role in the development and progression of these conditions.

•           Technological Advancements: Advances in sequencing technologies and bioinformatics have made it easier to study the human microbiome, identify specific microbes, and develop targeted therapies.

•           Increasing Investment: The human microbiome market growth has attracted significant investment from venture capitalists, pharmaceutical companies, and other investors, which is expected to drive innovation and growth in the industry.


Global Human Microbiome Market Recent Developments:

•           Expansion of Human Microbiome-based Therapies: Several companies are developing microbiome-based therapies for a range of diseases and conditions, including cancer, autoimmune diseases, and infections. These therapies involve using live bacteria, bacteriophages, or microbial metabolites to modulate the microbiome and improve health outcomes.

•           Increased Focus on Precision Medicine: Precision medicine, which involves tailoring treatments to an individual's genetic, environmental, and lifestyle factors, is becoming increasingly important in the microbiome field. Several companies are developing personalized human microbiome-based diagnostics and treatments to improve outcomes.

•           Advancements in Human Microbiome Research: Advances in human microbiome research are driving the development of new products and therapies. For example, researchers have discovered new bacterial strains with potential therapeutic benefits, and new tools for studying the human microbiome are enabling more precise and detailed analysis.

•           Growing Demand for Probiotics and Prebiotics: Probiotics and prebiotics, which are supplements that support the growth of beneficial human microbes in the gut, are becoming increasingly popular among consumers. As a result, several companies are developing new probiotic and prebiotic products.

•           Strategic Collaborations: Collaborations between industry players are becoming increasingly common in the human microbiome market. These collaborations are aimed at combining the strengths of different companies to develop new products and therapies.


Quickly Purchase Premium Copy of Human Microbiome Market Growth Report (2021-2028) at:

Global Human Microbiome Market Report Scope, Segmentations, Regional & Country Scope:

Report Coverage


Market Size Value in

USD 718.95 Million in 2021

Market Size Value by

USD 2,921.68 Million by 2028

Growth rate

CAGR of 22.2% from 2021-2028

Forecast Period


Base Year


No. of Pages


No. of Tables


No. of Charts & Figures


Historical data available


Segments covered

Product, Disease and Application and Geography

Regional scope

North America; Europe; Asia Pacific; Latin America; MEA

Country scope

US, UK, Canada, Germany, France, Italy, Australia, Russia, China, Japan, South Korea, Saudi Arabia, Brazil, Argentina

Report coverage

Revenue forecast, company ranking, competitive landscape, growth factors, and trends

Companies Covered

Rebiotix Inc, Yakult Honsha Co., Ltd, Synthetic Biologics Inc, DuPont, MaaT Pharma, Eligo Bioscience, Merck & Co. Inc, AOBiome LLC, Kaleido, Seres Therapeutics

Key Research Capabilities

Global Market Assessment, Business Development Strategies, Competitive Landscape, Opportunity Analysis, Regional and Country Level Market Analysis, Market Entry Strategies, Market Dynamics, Risk and Return Assessments, Pricing Analysis, Market Size and Forecasting, Company Profiling, Value Chain Analysis, Expansion Strategies, SWOT Analysis, New Product Development

Global Human Microbiome Market Insights: Key Developments

In July 2021, Seres Therapeutics, Inc. and Nestlé Health Science entered into commercialization license agreement to jointly commercialize SER-109, Seres’ investigational oral microbiome therapeutic for recurrent Clostridioides difficile infection (CDI), in the US and Canada.

In June 2021, MaaT Pharma received Data Safety and Monitoring Board (DSMB) approval to proceed with the phase 1b trial cohort study for testing the capsule formulation of microbiome ecosystem therapy.

Browse key market insights spread across 188 pages with 84 list of tables & 78 list of figures from the report, "Human Microbiome Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product (Probiotics, Foods, Prebiotics, Medical Foods, Diagnostic Device, Drugs and Supplements), Disease (Obesity, Diabetes, Autoimmune Disorders, Cancer, Mental Disorders, and Others) and Application (Therapeutics and Diagnostics) and Geography" in detail along with the table of contents:

North America is expected to hold the largest share of the human microbiome market growth in 2021. Its dominance in the global market is ascribed to the high concentration of market players in the US and Canada, surge in the number of conferences and meetings, and rising prevalence of chronic diseases. In February 2018, the 3rd Annual North America Microbiome Congress was held in San Diego by Kisaco Research, with a major focus on the gut, lung, oral, skin, and vaginal microbiome niches; it provided latest insights on microbiome research, clinical trials, and collaborative partnerships.

Based on product, the human microbiome market report is segmented into foods, medical foods, probiotics, prebiotics, drugs, diagnostic devices, and supplements. The probiotics segment is expected to lead the market in 2021 with a share of 24.71%. Based on disease, the human microbiome market is segmented into diabetes, cancer, autoimmune disorders, obesity, mental disorders, and other diseases.  The obesity segment is projected to hold the largest share of the market in 2021, whereas the diabetes segment is estimated to register the highest CAGR in the market during the forecast period. Based on application, the human microbiome market is segmented into diagnostics and therapeutics. The therapeutics segment is expected to hold a larger share of the market in 2021, and it is further estimated to register the highest CAGR during 2021–2028.

Rebiotix Inc., Yakult Honsha Co., Ltd., Synthetic Biologics, Inc., DuPont, MaaT Pharma, Eligo Bioscience, Merck & Co., Inc, AOBiome LLC, Kaleido; and Seres Therapeutics are among the key companies operating in the human microbiome market report. Leading players are focusing on the launch of new products, expansion and diversification of their market presence, and acquisition of other companies for tapping prevailing business opportunities.


About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.


Contact Us:

If you have any queries about this report or if you would like further information, please contact us:

Contact Person: Sameer Joshi


Phone: +1-646-491-9876

Press Release:



Back to news